SGRY vs WST
Surgery Partners, Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
SGRY
Surgery Partners, Inc.
48
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | SGRY | WST |
|---|
| AI Score |
48
|
74
|
| Price |
$15.02
|
$351.74
|
| P/E Ratio |
-21.74×
|
44.65×
|
| ROE |
-4.5%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
21.4%
|
36.8%
|
| Debt / Equity |
2.40×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
42.3
|
58.0
|
| Beta |
1.937
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SGRY versus WST.
WST leads by 26 points.
WST scores 74/100 (Buy) versus SGRY at 48/100 (Watch).
SGRY Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price-to-book of 1.2x is a discount to asset value — Value
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- ROE of only -4.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
- Revenue declining -20.5% YoY -- this is not a growth story right now — Growth
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical